Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Birch Hill Investment Advisors LLC

Birch Hill Investment Advisors LLC raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 90.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 738,779 shares of the medical research company’s stock after buying an additional 350,650 shares during the period. Edwards Lifesciences makes up about 2.5% of Birch Hill Investment Advisors LLC’s portfolio, making the stock its 13th biggest holding. Birch Hill Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $54,692,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Harbor Capital Advisors Inc. grew its position in Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after acquiring an additional 273 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST grew its holdings in shares of Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $3,702,000. Finally, Avanza Fonder AB acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $4,845,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,000 shares of company stock worth $547,430. 1.29% of the stock is owned by insiders.

Analysts Set New Price Targets

EW has been the topic of several analyst reports. Citigroup raised their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Piper Sandler dropped their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Truist Financial reaffirmed a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price objective for the company from $82.00 to $90.00 in a report on Monday, December 16th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $79.19.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $70.38 on Friday. The business has a 50 day simple moving average of $72.45 and a 200-day simple moving average of $69.43. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market capitalization of $41.51 billion, a PE ratio of 10.16, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.